Kari M Rosenkranz1, Karla Ballman2, Linda McCall3, Charlotte Kubicky4, Laurie Cuttino5, Huong Le-Petross6, Kelly K Hunt6, Armando Giuliano7, Kimberly J Van Zee8, Bruce Haffty9, Judy C Boughey10. 1. Dartmouth Hitchcock Medical Center, Lebanon, NH, USA. kari.m.rosenkranz@hitchcock.org. 2. Alliance Statistics and Data Center, Weill Medical College of Cornell University, New York, NY, USA. 3. Alliance Statistics and Data Center, Duke University, Durham, NC, USA. 4. Oregon Health and Science University, Portland, OR, USA. 5. Virginia Commonwealth University Health System, Richmond, VA, USA. 6. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Cedars-Sinai Medical Center, Los Angeles, CA, USA. 8. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 10. Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND: Historically, multiple ipsilateral breast cancer (MIBC) has been a contraindication to breast-conserving therapy (BCT). We report the feasibility of BCT in MIBC from the ACOSOG Z11102 trial [Alliance], a single arm noninferiority trial of BCT for women with two or three sites of malignancy in the ipsilateral breast. METHODS: Women who enrolled preoperatively in ACOSOG Z11102 were evaluated for conversion to mastectomy and need for reoperation to obtain negative margins. Characteristics of women who successfully underwent BCT and those who converted to mastectomy were compared. Factors were examined for association with the need for margin reexcision. RESULTS: Of 198 patients enrolled preoperatively, 190 (96%) had 2 foci of disease. Median size of the largest tumor focus was 1.5 (range 0.1-7.0) cm; 49 patients (24.8%) had positive nodes. There were 14 women who underwent mastectomy due to positive margins, resulting in a conversion to mastectomy rate of 7.1% (95% confidence interval [CI] 3.9-10.6%). Of 184 patients who successfully completed BCT, 134 completed this in a single operation. Multivariable logistic regression analysis did not identify any factors significantly associated with conversion to mastectomy or need for margin reexcision. CONCLUSIONS: Breast conservation is feasible in MIBC with 67.6% of patients achieving a margin-negative excision in a single operation and 7.1% of patients requiring conversion to mastectomy due to positive margins. No characteristic was identified that significantly altered the risk of conversion to mastectomy or need for reexcision. CLINICALTRIALS. GOV IDENTIFIER: NCT01556243.
BACKGROUND: Historically, multiple ipsilateral breast cancer (MIBC) has been a contraindication to breast-conserving therapy (BCT). We report the feasibility of BCT in MIBC from the ACOSOG Z11102 trial [Alliance], a single arm noninferiority trial of BCT for women with two or three sites of malignancy in the ipsilateral breast. METHODS:Women who enrolled preoperatively in ACOSOG Z11102 were evaluated for conversion to mastectomy and need for reoperation to obtain negative margins. Characteristics of women who successfully underwent BCT and those who converted to mastectomy were compared. Factors were examined for association with the need for margin reexcision. RESULTS: Of 198 patients enrolled preoperatively, 190 (96%) had 2 foci of disease. Median size of the largest tumor focus was 1.5 (range 0.1-7.0) cm; 49 patients (24.8%) had positive nodes. There were 14 women who underwent mastectomy due to positive margins, resulting in a conversion to mastectomy rate of 7.1% (95% confidence interval [CI] 3.9-10.6%). Of 184 patients who successfully completed BCT, 134 completed this in a single operation. Multivariable logistic regression analysis did not identify any factors significantly associated with conversion to mastectomy or need for margin reexcision. CONCLUSIONS: Breast conservation is feasible in MIBC with 67.6% of patients achieving a margin-negative excision in a single operation and 7.1% of patients requiring conversion to mastectomy due to positive margins. No characteristic was identified that significantly altered the risk of conversion to mastectomy or need for reexcision. CLINICALTRIALS. GOV IDENTIFIER: NCT01556243.
Authors: Suzanne Coopey; Barbara L Smith; Stephanie Hanson; Julliette Buckley; Kevin S Hughes; Michele Gadd; Michelle C Specht Journal: Ann Surg Oncol Date: 2011-06-01 Impact factor: 5.344
Authors: L Hadzikadic Gusic; K P McGuire; T Ozmen; A Soran; C R Thomas; P F McAuliffe; E J Diego; M Bonaventura; R R Johnson; G M Ahrendt Journal: J Surg Oncol Date: 2013-12-11 Impact factor: 3.454
Authors: Richard J Bleicher; Robin M Ciocca; Brian L Egleston; Linda Sesa; Kathryn Evers; Elin R Sigurdson; Monica Morrow Journal: J Am Coll Surg Date: 2009-06-18 Impact factor: 6.113
Authors: Oreste Gentilini; Edoardo Botteri; Nicole Rotmensz; Luciana Da Lima; Mujgan Caliskan; Carlos A Garcia-Etienne; Irina Sosnovskikh; Mattia Intra; Giovanni Mazzarol; Simona Musmeci; Paolo Veronesi; Viviana Galimberti; Alberto Luini; Giuseppe Viale; Aron Goldhirsch; Umberto Veronesi Journal: Breast Cancer Res Treat Date: 2008-03-11 Impact factor: 4.872
Authors: J M Kurtz; J Jacquemier; R Amalric; H Brandone; Y Ayme; D Hans; C Bressac; J M Spitalier Journal: Ann Surg Date: 1990-07 Impact factor: 12.969
Authors: Kari M Rosenkranz; Karla Ballman; Linda McCall; Colleen McCarthy; Charlotte D Kubicky; Laurie Cuttino; Kelly K Hunt; Armando Giuliano; Kimberly J Van Zee; Bruce Haffty; Judy C Boughey Journal: Ann Surg Oncol Date: 2020-07-22 Impact factor: 5.344
Authors: Y A Masannat; A Agrawal; L Maraqa; M Fuller; S K Down; Ssk Tang; D Pang; M Kontos; L Romics; S D Heys Journal: Ann R Coll Surg Engl Date: 2019-09-06 Impact factor: 1.891
Authors: Laurie W Cuttino; Linda McCall; Charlotte Kubicky; Karla V Ballman; Huong Le-Petross; Kelly K Hunt; Bruce Haffty; Kari M Rosenkranz; Judy C Boughey Journal: Int J Radiat Oncol Biol Phys Date: 2021-10-08 Impact factor: 7.038
Authors: Francesca Savioli; Subodh Seth; Elizabeth Morrow; Julie Doughty; Sheila Stallard; Andy Malyon; Laszlo Romics Journal: Breast Cancer (Dove Med Press) Date: 2021-05-25
Authors: Oluwadamilola M Fayanju; Yi Ren; Samantha M Thomas; Rachel A Greenup; Terry Hyslop; E Shelley Hwang; John H Stewart Journal: JNCI Cancer Spectr Date: 2019-12-16